Kirk William Johnson

This inventor holds 36 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Antibody Therapeutics. Top assignees: Chiron Corporation, Xoma (US) LLC, Ammax Bio, Inc.. Active years: 1998-2025.

USPTO Granted Patents = 36 (Patent Applications = 13)

% Patents Active = 77.8

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 237(Granted Patents)

Location History:

Alameda, CA (US) (2009)
Berkeley, CA (US) (2019)
Moraga, CA (US) (1998 - 2023)
Emeryville, CA (US) (2023)

Company Filing History:

Baxter International Inc.

Musc Foundation for Research Development

patents

11. 2 out of 245

Novartis Vaccines & Diagnostics, Gmbh

patents

12. 2 out of 1,447

University of Colorado

patents

13. 1 out of 2

Central Laboratory of the Netherlands Red Cross Blood Transfusion Service

15. 3 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2025

Loading Chart...

Areas of Expertise:

Antibodies

CSF1R

Cytokine Regulation

Formulations

Parathyroid Hormone

Insulin Receptor

Sulfated Polysaccharides

Glycogen Synthase Kinase 3

Fucoidan Purification

Neuropathic Pain

Interleukin-2

Drug Addictions

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12371501 - Extended local release of anti-CSFR1 antibodies (2025-07-29),

2. 12234285 - Antibodies that bind interleukin-2 and uses thereof (2025-02-25),

3. 12178915 - High concentration formulations of anti-CSF1 and anti-CSF1R antibodies (2024-12-31),

4. 11787876 - Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof (2023-10-17),

5. 11752096 - Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumors (2023-09-12),

6. 11427641 - Extended local release of anti-CSFR1 antibodies (2022-08-30),

7. 11419822 - High concentration formulations of anti-CSF1 and anti-CSF1R antibodies (2022-08-23),

8. 10858428 - Antibodies that bind interleukin-2 and uses thereof (2020-12-08),

9. 10711067 - Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery (2020-07-14),

10. 10519250 - Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof (2019-12-31),

11. 10253101 - Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia (2019-04-09),

12. 9234051 - Methods for fucoidan purification from seaweed extracts (2016-01-12),

13. 8859526 - Methods for treating bleeding disorders using sulfated polysaccharides (2014-10-14),

14. 8771973 - Methods for treating bleeding disorders using sulfated polysaccharides (2014-07-08),

15. 8748595 - Methods for fucoidan purification from sea weed extracts (2014-06-10),

Title: Kirk William Johnson: Pioneering Innovator in Biomedical Research

Introduction: Kirk William Johnson, a prolific inventor based in Moraga, CA (US), has made significant contributions to the field of biomedical research. With an impressive portfolio of 33 patents to his name, Johnson stands out as a leading figure in the development of novel therapies for a range of medical conditions.

Latest Patents:

1. "Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof": Johnson's groundbreaking work on human antibodies against human parathyroid hormone receptor 1 (PTH1R) has paved the way for innovative treatment options in cancer, Humoral Hypercalcemia of Malignancy (HHM), and various hyperparathyroidism conditions.

2. "Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumors": Johnson's research on intra-articular delivery of anti-CSF1R antibodies has revolutionized the treatment of diseases impacted by CSF1/CSF1R inhibition, demonstrating sustained exposure and pharmacologic activity in joints for extended therapeutic benefits.

Career Highlights: Johnson's professional journey includes impactful roles at renowned companies like Chiron Corporation and Baxter International Inc. His multidisciplinary expertise has enabled him to drive innovation and make a tangible difference in the healthcare industry.

Collaborations: Throughout his career, Johnson has collaborated with esteemed colleagues such as Rustum S Boyce and John M Nuss. These partnerships have been instrumental in advancing cutting-edge research and translating scientific discoveries into real-world applications.

Conclusion: Kirk William Johnson's pioneering spirit, coupled with his dedication to pushing the boundaries of biomedical innovation, has positioned him as a trailblazer in the field. His relentless pursuit of scientific excellence continues to inspire and shape the future of healthcare.